Online citations, reference lists, and bibliographies.

Adverse Outcomes Of Long-term Use Of Proton Pump Inhibitors: A Systematic Review And Meta-analysis

M. M. Islam, T. N. Poly, B. Walther, N. Dubey, D. N. Anggraini Ningrum, Syed-Abdul Shabbir, Yu-Chuan Jack Li
Published 2018 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
The association between the long-term use of proton pump inhibitors (PPIs) and the risks of various diseases remains controversial. Therefore, the primary objective of this study was to quantify the associations as presented in the literature and to also provide this information to healthcare professionals and patients about their potentially adverse effects. In July 2016, we searched through Medline (PubMed), Embase, and the Cochrane Library from inception using common keywords. We included observational studies that provided risk estimates on the long-term use of PPIs and their adverse effects. Overall, 43 studies were included in the systematic review, of which 28 studies were also included in the random effect meta-analysis. Odds of community-acquired pneumonia, hip fracture, and colorectal cancer were 67% [odds ratio (OR)=1.67; 95% confidence interval (CI): 1.04–2.67], 42% (OR=1.42; 95% CI: 1.33–1.53), and 55% (OR=1.55; 95% CI: 0.88–2.73) higher in patients with long-term PPIs use compared with patients who did not use PPIs. Although the use of PPIs provides short-term health benefits, their prolonged use is associated with minor and also potentially major adverse health outcomes. Hence, we strongly recommend that the prescription of PPIs should be done with caution to improve the medication’s efficacy and patients’ safety.
This paper references
10.1001/jama.2013.280490
Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency.
Jameson R. Lam (2013)
10.1001/jama.283.15.2008
Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.
D. Stroup (2000)
10.1016/j.jcin.2010.12.009
Clopidogrel and proton pump inhibitors: influence of pharmacological interactions on clinical outcomes and mechanistic explanations.
Udaya S. Tantry (2011)
10.1016/j.annepidem.2014.01.004
Proton-pump inhibitor use and hip fractures in men: a population-based case-control study.
A L Adams (2014)
Proton Pump Inhibitor Use and Risk of Colorectal Cancer: A Population-Based, CaseControl Study
Douglas J. Robertson (2007)
10.3748/WJG.V16.I28.3573
Proton pump inhibitors as a risk factor for recurrence of Clostridium-difficile-associated diarrhea.
Ji Won Kim (2010)
10.1371/journal.pmed.1001736
Proton Pump Inhibitors and Hospitalization with Hypomagnesemia: A Population-Based Case-Control Study
Jonathan Zipursky (2014)
10.1007/s40264-013-0093-z
Use of Acid-Suppressive Drugs in Pregnancy and the Risk of Childhood Asthma: Bidirectional Crossover Study using the General Practice Research Database
Eelko Hak (2013)
10.1176/foc.1.2.213
Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2004.
L. Johnston (2000)
10.1002/pds.2026
Use of proton pump inhibitors increased the risk of hip fracture: a population-based case-control study.
H C Chiu (2010)
10.1016/j.amjmed.2011.01.007
Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies.
Elaine W. Yu (2011)
10.1177/2042098613482484
Proton pump inhibitors and risk of vitamin and mineral deficiency: evidence and clinical implications
Joel J. Heidelbaugh (2013)
10.1001/jamaneurol.2015.4791
Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis.
Willy Gomm (2016)
10.1016/j.maturitas.2014.05.019
Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women. The WHILA study.
L Moberg (2014)
10.1001/jamainternmed.2015.7193
Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease.
Benjamin M. Lazarus (2016)
10.1093/ajhp/56.suppl_4.s11
Safety profile of the proton-pump inhibitors.
J. P. Reilly (1999)
10.1007/s00198-015-3168-0
Use of proton pump inhibitors is associated with fractures in young adults: a population-based study
Daniel E Freedberg (2015)
10.1136/gutjnl-2013-304738
Proton pump inhibitors and the risk of hospitalisation for community-acquired pneumonia: replicated cohort studies with meta-analysis
K. Filion (2013)
Long-term high-dose proton pump inhibitor administration to Helicobacter pylori-infected Mongolian gerbils enhances neuroendocrine tumor development in the glandular stomach.
Hironobu Tsukamoto (2011)
10.1053/j.gastro.2008.08.045
American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease.
Peter J. Kahrilas (2008)
10.1016/j.jclinepi.2009.06.006
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.
Alessandro Liberati (2009)
10.1001/archinte.167.9.950
Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study.
Sinem Ezgi Gulmez (2007)
H2 receptor antagonists and proton pump inhibitors in general practice: prescribing trends in the UK
R Martin (1991)
10.1002/jcph.316
The association of proton pump inhibitors and hypomagnesemia in the community setting.
Noa Markovits (2014)
10.3945/ajcn.112.047142
Is everything we eat associated with cancer? A systematic cookbook review.
Jonathan D Schoenfeld (2013)
10.7326/0003-4819-149-6-200809160-00005
Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia
Monika Sarkar (2008)
10.4162/nrp.2010.4.3.229
Dietary source of vitamin B12 intake and vitamin B12 status in female elderly Koreans aged 85 and older living in rural area
Chung Shil Kwak (2010)
10.1007/s12265-011-9334-7
The Clinical Relevance of the Clopidogrel–Proton Pump Inhibitor Interaction
Atif Mohammad (2012)
10.1016/j.bone.2012.09.028
Use of proton pump inhibitors and risk of fragility hip fracture in a Mediterranean region.
C. Reyes (2013)
10.1371/journal.pone.0124653
Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population
Nigam Haresh Shah (2015)
10.1046/j.1365-2036.2003.01600.x
Hospital use of acid-suppressive medications and its fall-out on prescribing in general practice: a 1-month survey.
F. Parente (2003)
10.1002/pds.1978
Use of proton pump inhibitors and H2 blockers and risk of pneumonia in older adults: a population-based case-control study.
Sascha Dublin (2010)
10.1136/bmjopen-2014-006710
Population-based cohort study on the risk of pneumonia in patients with non-traumatic intracranial haemorrhage who use proton pump inhibitors
Sai-Wai Ho (2014)
troesophageal reflux disease
NJ Shaheen (2008)
10.1111/j.1572-0241.2006.00723.x
The Burden of Gastrointestinal and Liver Diseases, 2006
N. Shaheen (2006)
10.1503/cmaj.1040876
Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies
S. Dial (2004)
10.1016/j.ijcard.2014.09.036
Proton pump inhibitor use represents an independent risk factor for myocardial infarction.
Chia-Jen Shih (2014)
10.1111/j.1365-2710.2009.01100.x
Proton pump inhibitors: predisposers to Alzheimer disease?
Mohammad Kazem Fallahzadeh (2010)
10.1016/j.gie.2005.08.043
Colorectal neoplasia in veterans is associated with Barrett's esophagus but not with proton-pump inhibitor or aspirin/NSAID use.
Peter D Siersema (2006)
10.1053/j.ajkd.2013.02.373
Out-of-hospital use of proton pump inhibitors and hypomagnesemia at hospital admission: a nested case-control study.
Ioannis Koulouridis (2013)
10.1016/0140-6736(91)91887-Z
Sexual disturbances during omeprazole therapy
J. P. Dutertre (1991)
10.1038/ajg.2013.333
Proton Pump Inhibitors and Risk for Recurrent Clostridium difficile Infection Among Inpatients
Daniel E Freedberg (2013)
Autoimmune hemolytic anemia.
C. Engelfriet (1992)
Worldwide prevalence of anaemia 1993-2005: WHO global database on anaemia.
B. Benoist (2008)
10.1038/ajg.2010.409
Treatment of GERD and Proton Pump Inhibitor Use in the Elderly: Practical Approaches and Frequently Asked Questions
Shannon Scholl (2011)
Underlying Cause of Death 1999–2013 on CDC WONDER Online Database, released
CDC (2015)
10.3322/caac.21166
Cancer statistics, 2013.
Rebecca L Siegel (2013)
10.14740/jocmr2322w
Proton Pump Inhibitors Did Not Increase Risk of Pneumonia in Patients With Chronic Obstructive Pulmonary Disease
S W Lee (2015)
10.1038/ki.2012.452
Proton-pump inhibitor use is associated with low serum magnesium concentrations.
John I. Danziger (2013)
10.1007/s00223-014-9855-6
The Relationship Between Proton Pump Inhibitor Adherence and Fracture Risk in the Elderly
Jian Ding (2014)
10.1053/j.gastro.2010.03.055
Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients.
Douglas A. Corley (2010)
10.1016/j.jmii.2013.10.004
Proton pump inhibitor usage and the associated risk of pneumonia in patients with chronic kidney disease.
Chih-Hung Chen (2015)
10.1161/CIRCULATIONAHA.113.003602
Unexpected Effect of Proton Pump Inhibitors: Elevation of the Cardiovascular Risk Factor Asymmetric Dimethylarginine
Yohannes T. Ghebremariam (2013)
Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study
M Charlot (2010)
10.1001/jama.294.23.2989
Use of Gastric Acid–Suppressive Agents and the Risk of Community-Acquired Clostridium difficile–Associated Disease
S. Dial (2005)
10.1038/ajg.2012.200
The Relationship Between Proton Pump Inhibitor Use and Longitudinal Change in Bone Mineral Density: A Population-Based From the Canadian Multicentre Osteoporosis Study (CaMos)
L. Targownik (2012)
10.1023/A:1011278030001
An evaluation of the use of proton pump inhibitors
Neil M Walker (2001)
Use of Proton Pump Inhibitors Correlates with Increased Risk of Pancreatic Cancer: A Case-Control Study in Taiwan
Shih-Wei Lai (2014)
10.1136/bmj.327.7414.557
Measuring inconsistency in meta-analyses
J. Higgins (2003)
10.1053/j.gastro.2007.06.022
Chronic proton pump inhibitor therapy and the risk of colorectal cancer.
Yu-Xiao Yang (2007)
10.1111/j.1365-2125.2012.04250.x
Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan.
Chen-Fang Lin (2012)
10.1001/jama.1990.03440220087036
Frequency of hypomagnesemia and hypermagnesemia. Requested vs routine.
Robert Whang (1990)
10.3748/wjg.v21.i15.4599
Influence of proton pump inhibitors on gastritis diagnosis and pathologic gastric changes.
Soumana C Nasser (2015)
10.1053/j.ajkd.2015.05.012
Proton pump inhibitors and hypomagnesemia in the general population: a population-based cohort study.
Brenda C T Kieboom (2015)
Alzheimer ’ s disease facts and fi gures
R Siegel (2015)
10.1001/jama.292.16.1955
Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.
R. Laheij (2004)
10.1111/ggi.12047
Prescribing patterns of proton pump inhibitors in older hospitalized patients in a Scottish health board.
Anna Amrit Jarchow-Macdonald (2013)
10.1007/s13197-011-0290-7
Utilization of byproducts and waste materials from meat, poultry and fish processing industries: a review
K. Jayathilakan (2011)
10.1007/s00223-008-9170-1
Acid-Suppressive Medications and Risk of Bone Loss and Fracture in Older Adults
Elaine W Yu (2008)
10.1007/s12350-015-0096-5
Myocardial viability as integral part of the diagnostic and therapeutic approach to ischemic heart failure
Jeroen J. Bax (2015)
10.1136/gut.2005.086579
Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK
L. Rodríguez (2006)
10.1001/archinternmed.2010.73
Proton pump inhibitors and risk for recurrent Clostridium difficile infection.
Amy Linsky (2010)
10.1371/journal.pone.0128004
Risk of Community-Acquired Pneumonia with Outpatient Proton-Pump Inhibitor Therapy: A Systematic Review and Meta-Analysis
Allison A. Lambert (2015)
10.1345/aph.1R556
Proton Pump Inhibitor–Associated Hypomagnesemia: What Do FDA Data Tell Us?
Chee Phun Luk (2013)
10.1186/1471-2288-13-82
Proton pump inhibitors and the risk of pneumonia: a comparison of cohort and self-controlled case series designs
E. Ramsay (2013)
Rosen's Emergency Medicine: Concepts and Clinical Practice
P. Rosén (2002)
10.7326/0003-4819-152-6-201003160-00003
Outcomes With Concurrent Use of Clopidogrel and Proton-Pump Inhibitors
W. Ray (2010)
10.1016/S0946-672X(11)80026-X
Pathogenetic mechanisms of hypomagnesemia in alcoholic patients.
Moses S Elisaf (1995)
An Unexpected Effect of Proton Pump Inhibitors : Elevation of the Cardiovascular Risk Factor ADMA
Yohannes T. Ghebremariam (2013)
10.2169/INTERNALMEDICINE.49.4064
Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists.
Shaker M. Eid (2010)
10.1038/ki.2014.74
A nationwide nested case-control study indicates an increased risk of acute interstitial nephritis with proton pump inhibitor use
Mei-Ling Blank (2014)
Use of proton pump inhibitors (PPI) and history of earlier fracture are independent risk factors for fracture in postmenopausal women
LM Moberg (2014)
10.3233/JAD-2010-1262
Selective interaction of lansoprazole and astemizole with tau polymers: potential new clinical use in diagnosis of Alzheimer's disease.
Leonel E. Rojo (2010)
Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor.
John Mark Ruscin (2002)
10.1007/s11096-006-9028-4
Continuation of Proton Pump Inhibitors from Hospital to Community
Kenneth Grant (2006)
10.1111/j.1572-0241.2000.02680.x
Overuse of acid-suppressive therapy in hospitalized patients
R. Nardino (2000)
10.1136/gut.2004.051821
Epidemiology of gastro-oesophageal reflux disease: a systematic review
J. Dent (2005)
10.1016/j.rmed.2012.04.008
The natural history of community-acquired pneumonia in COPD patients: a population database analysis.
Hana Müllerova (2012)
10.1093/cid/cir767
Risk of community-acquired pneumonia in veteran patients to whom proton pump inhibitors were dispensed.
John A. Hermos (2012)
10.1016/j.jclinepi.2003.08.015
A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults.
R. Valuck (2004)
10.1111/j.1365-2710.2000.00312.x
Overuse of proton pump inhibitors.
M. Naunton (2000)
10.1038/bjc.2011.511
Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case–control study
M. Bradley (2012)
10.1186/1471-2369-14-150
Proton pump inhibitors and acute kidney injury: a nested case–control study
Donald G. Klepser (2013)
10.1001/jama.296.24.2947
Long-term proton pump inhibitor therapy and risk of hip fracture.
Yu-Xiao Yang (2006)
10.1007/s00198-016-3510-1
Gastroesophageal reflux disease with proton pump inhibitor use is associated with an increased risk of osteoporosis: a nationwide population-based analysis
C.-H. Chen (2016)
10.1002/14651858.MR000034.pub2
Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials.
Andrew T Anglemyer (2014)
10.1002/sim.1186
Quantifying heterogeneity in a meta-analysis.
J. Higgins (2002)
10.1183/09031936.00095807
New evidence of risk factors for community-acquired pneumonia: a population-based study
Jordi Almirall (2008)
10.1053/j.gastro.2009.11.014
Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
L. Targownik (2010)
10.1001/archinternmed.2010.94
Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative.
S. Gray (2010)
10.1097/OGX.0000000000000306
Trends in Prescription Drug Use Among Adults in the United States From 1999–2012
Elizabeth D. Kantor (2016)
10.1002/pds.3329
Proton pump inhibitors and traditional nonsteroidal anti-inflammatory drugs and the risk of acute interstitial nephritis and acute kidney injury.
Charles E. Leonard (2012)
10.1002/phar.1410
Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting.
Lucía Cea Soriano (2014)
10.1136/bmj.317.7156.452
Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database
James Bashford (1998)
10.1111/ijcp.12469
Impact of proton pump inhibitor use on magnesium homoeostasis: a cross-sectional study in a tertiary emergency department.
G. Lindner (2014)
10.3748/wjg.v18.i18.2161
Clopidogrel and proton pump inhibitors--where do we stand in 2012?
Michael Drepper (2012)
H 2 receptor antagonists and proton pump inhibitors in general practice : prescribing trends in the UK from 1991 to 1996
R Martin (2011)
How safe are popular reflux drugs? Experts debate evidence linking acid-blockers to possible bone, heart problems
K. Pallarito (2009)
10.1097/EDE.0b013e3181b5f27d
Acid-suppressive Drugs and Community-acquired Pneumonia
Luis Garcia Rodriguez (2009)
10.7314/APJCP.2015.16.14.5741
Epidemic Trends of Upper Gastrointestinal Tract Abnormalities: Hospital-based study on Endoscopic Data Evaluation.
Mohammed Khaliq Mohiuddin (2015)
10.1002/pds.2202
Relationship between cardiovascular outcomes and proton pump inhibitor use in patients receiving dual antiplatelet therapy after acute coronary syndrome.
Fei-Yuan Hsiao (2011)
10.2165/00002018-200831080-00004
Association Between Use of Acid-Suppressive Drugs and Risk of Gastric Cancer
Hani Tamim (2008)
10.1046/j.1365-2125.2000.00262.x
The rates of common adverse events reported during treatment with proton pump inhibitors used in general practice in England: cohort studies.
Richard M. Martin (2000)
10.1212/WNL.0b013e31828726f5
Alzheimer disease in the United States (2010–2050) estimated using the 2010 census
Liesi E. Hebert (2013)
10.1136/bmj.309.6969.1620
Arthralgias and omeprazole.
M Beutler (1994)
10.1111/j.1365-2036.2009.04229.x
Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection.
Rossella Turco (2010)
10.1002/j.1875-9114.2012.01112.x
Effect of the clopidogrel-proton pump inhibitor drug interaction on adverse cardiovascular events in patients with acute coronary syndrome.
Sharvari M Bhurke (2012)
10.1007/s10620-011-1589-y
Association Between Proton Pump Inhibitor Use and Anemia: A Retrospective Cohort Study
Erin Sarzynski (2011)
10.1093/oxfordjournals.epirev.a036298
Quantitative methods in the review of epidemiologic literature.
Sander Greenland (1987)
10.1111/j.1365-2036.2008.03924.x
Proton pump inhibitors increase significantly the risk of Clostridium difficile infection in a low-endemicity, non-outbreak hospital setting.
Bruce R Dalton (2009)
10.2459/JCM.0b013e3283416b6b
One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study
Paolo Ortolani (2012)
10.1007/s00198-010-1337-8
Use of proton pump inhibitors and risk of hip/femur fracture: a population-based case-control study
Sander Pouwels (2010)
10.1111/j.1572-0241.2007.01665.x
Proton Pump Inhibitors and the Risk of Colorectal Cancer
Eva M. van Soest (2008)
10.1111/j.1742-1241.2004.00298.x
Proton pump inhibitors: a survey of prescribing in an Irish general hospital.
A Z Mat Saad (2005)
10.1586/ecp.12.20
Are proton pump inhibitors associated with the development of community-acquired pneumonia? A meta-analysis
Christopher Alan Giuliano (2012)
10.1016/S0140-6736(95)90449-2
Acute gout associated with omeprazole
Arnoldo Kraus (1995)
10.1016/0140-6736(92)92205-T
Subacute myopathy during omeprazole therapy
Francisco Javier Guerra Garrote (1992)
10.1177/1756283X12437358
Overutilization of proton-pump inhibitors: what the clinician needs to know
Joel J. Heidelbaugh (2012)
10.1136/bmj.39406.449456.BE
Overprescribing proton pump inhibitors
Ian Forgacs (2008)
10.1371/journal.pone.0058837
The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production
Nahuai Badiola (2013)
10.1111/jebm.12141
The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta-analysis, and clinical practice guideline: a systematic review.
Xiantao Zeng (2015)
10.1037/e400412005-001
Monitoring the Future: National Results on Adolescent Drug Use. Overview of Key Findings, 2003. NIH Publication No. 04-5506.
L. Johnston (2004)
10.1111/j.1365-2036.1994.tb00211.x
Continuing development of acid pump inhibitors: site of action of pantoprazole.
Jai Moo Shin (1994)
10.1007/s00535-012-0722-9
A population-based case–control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate
Joongyub Lee (2012)
10.1046/j.1365-2036.1996.27169000.x
Effect of short- and long-term treatment with omeprazole on the absorption and serum levels of cobalamin.
B. Schenk (1996)



This paper is referenced by
10.1093/cid/ciy671
A Case-Control Study: Clinical Characteristics of Nosocomial Bloodstream Infections Versus Non-bloodstream Infections of Acinetobacter spp.
Su Xin Xu (2018)
10.1007/s42399-020-00268-2
Proton Pump Inhibitors: for What and for How Long
Thakul Rattanasuwan (2020)
10.1007/s00198-018-4788-y
Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies
Tahmina Nasrin Poly (2018)
10.1053/j.gastro.2019.07.067
Safety of proton pump inhibitors questioned based on a large randomized trial of patients receiving rivaroxaban or aspirin.
Johanna Simin (2019)
10.2147/DMSO.S237454
Metformin and Micronutrient Status in Type 2 Diabetes: Does Polypharmacy Involving Acid-Suppressing Medications Affect Vitamin B12 Levels?
Michael Wakeman (2020)
10.1002/ncp.10217
Response to Comment on 'Proton Pump Inhibitors. Risks and Rewards and Emerging Consequences to the Gut Microbiome'.
Amandeep Singh (2019)
10.1002/ncp.10218
Comment on 'Proton Pump Inhibitors. Risks and Rewards and Emerging Consequences to the Gut Microbiome'.
Katsuhiro Toda (2019)
10.3748/wjg.v25.i22.2706
Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified
Giovanni Bruno (2019)
10.1136/bmjqs-2019-010411
Education as a low-value improvement intervention: often necessary but rarely sufficient
Christine Soong (2019)
10.1111/codi.14968
Associations Between Gastric Histopathology and the Occurrence of Colon Polyps.
Amnon Sonnenberg (2020)
10.1016/S2468-1253(19)30408-X
The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017
M Ashworth Dirac (2020)
10.1186/s12916-019-1428-0
Aspirin for primary prevention of cardiovascular disease: a meta-analysis with a particular focus on subgroups
Georg Gelbenegger (2019)
10.1007/s00535-019-01652-z
Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden
Nele Brusselaers (2019)
10.1097/MEG.0000000000001301
No influence of cannabis use on liver stiffness in HIV-HCV co-infected patients (ANRS CO13 HEPAVIH cohort study)
Fabienne Marcellin (2019)
10.2215/CJN.10110818
Proton Pump Inhibitors in Kidney Disease.
Benjamin M. Lazarus (2018)
10.7326/M19-1795
Management of Nonvariceal Upper Gastrointestinal Bleeding: Guideline Recommendations From the International Consensus Group
A. Barkun (2019)
10.1007/s00228-020-02854-8
Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis
H. Song (2020)
Semantic Scholar Logo Some data provided by SemanticScholar